Delivery Order SPE2DB22D3501-SPE2DB24FVL52
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,304.72 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen. The contract has a ceiling value of $3,304.72 and a completion date of November 7, 2022. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award, valued at $11,668.82, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract covers the delivery of Dupixent 300 mg/2 ml pen, a pharmaceutical product, with a performance period through December 5, 2023. The contract is a Firm Fixed Price Delivery Order, and was not set aside for any specific business type. Amerisourcebergen Drug Corp is a major pharmaceutical distributor...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $9,936.76 delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen, with a completion date of December 28, 2023. The contract is a firm-fixed-price delivery order and was not set aside for any specific business category. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of pharmaceutical products, including Dupixent 300 mg/2 ml pens. The contract, valued at $16,272.14, has a completion date of June 5, 2023 and is a Firm Fixed Price Delivery Order. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $6,024.73 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml pen, with a completion date of November 8, 2023. The contract is not designated with a set-aside. Amerisourcebergen Drug Corp, a major pharmaceutical distributor, holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Dupixent 300 mg/2 ml pen, valued at $5,733.25. The award is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC), which has a ceiling value of $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and...
- This federal contract award is for the delivery of Dupixent 200 mg/1.14 ml pens to the U.S. government. The award was issued to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $8,236.04 and an ultimate completion date of October 19, 2023. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order (SPE2DB20D1050|SPE2DB24FH50M) with a ceiling value of $5,084.17. The contract is for the supply of DUPIXENT 300 MG/2 ML PEN 2ML, a specialty pharmaceutical product. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of February 9, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award, valued at $9,019.92, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of the pharmaceutical product Dupixent 300 mg/2 ml pen, with a completion date of June 2, 2022. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary...
- This federal contract award to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Dupixent 300 mg/2 ml pens. The $16,429.16 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA) and has an ultimate completion date of August 29, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle for providing a comprehensive range of...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB24FVL52Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The award, with a ceiling value of $5,005.47, is for the delivery of Dupixent 300 mg/2 ml pen, a pharmaceutical product. The contract has an ultimate completion date of April 29, 2024 and is a firm fixed-price delivery order. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 4/26/24 |